phosphoric acid dibenzyl ester trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)-2,5-dioxo-pyrrolidin-1-ylmethyl ester

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: phosphoric acid dibenzyl ester trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)-2,5-dioxo-pyrrolidin-1-ylmethyl ester
• 英文别名: [(3S,4S)-3-(1-azatricyclo[6.3.1.04,12]dodeca-2,4,6,8(12)-tetraen-3-yl)-4-(1H-indol-3-yl)-2,5-dioxopyrrolidin-1-yl]methyl dibenzyl phosphate
• 化学式: C₃₈H₃₄N₃O₆P
• 分子量: 659.678
• InChiKey: CERMWDQSQWFRBF-VSJLXWSYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  48
• 可旋转键数：
  11
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  103
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  phosphoric acid dibenzyl ester trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)-2,5-dioxo-pyrrolidin-1-ylmethyl ester 在 palladium 10% on activated carbon 、 氢气 作用下， 以 甲醇 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 2.0h， 生成 (±)-phosphoric acid mono-[trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)-2,5-dioxopyrrolidin-1-ylmethyl]ester
  参考文献：
  名称：

  COMBINATIONAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER

  摘要：

  本发明提供了治疗细胞增殖紊乱（如癌症）的方法，通过向需要的受试者投予一种吡啶喹啉基吡咯-2,5-二酮化合物或吡啶喹啉基吡咯啉-2,5-二酮化合物的治疗有效量，与第二种抗增殖剂的治疗有效量结合使用。

  公开号：

  US20150328208A1
• 作为产物：
  描述：

  5,6-二氢-4H-吡咯并[3,2,1-ij]喹啉-1-羧酸乙酯 在 四氮唑 、 盐酸 、 potassium tert-butylate 、 水 、 mercury dichloride 、 sodium hydroxide 、 锌 作用下， 以 四氢呋喃 、 喹啉 、 乙醚 、 乙醇 、 水 、 乙腈 、 叔丁醇 为溶剂， 反应 23.0h， 生成 phosphoric acid dibenzyl ester trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)-2,5-dioxo-pyrrolidin-1-ylmethyl ester
  参考文献：
  名称：

  COMBINATIONAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER

  摘要：

  本发明提供了治疗细胞增殖紊乱（如癌症）的方法，通过向需要的受试者投予一种吡啶喹啉基吡咯-2,5-二酮化合物或吡啶喹啉基吡咯啉-2,5-二酮化合物的治疗有效量，与第二种抗增殖剂的治疗有效量结合使用。

  公开号：

  US20150328208A1

文献信息

• Compositions and methods for treatment of cancer
  申请人：Li J. Chiang

  公开号：US20060223760A1

  公开（公告）日：2006-10-05

  The present invention relates to pyrroloquinolinyl-pyrrole-2,5-dione compounds and pyrroloquinolinyl-pyrrolidine-2,5-dione compounds, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising pyrroloquinolinyl-pyrrole-2,5-dione compounds and pyrroloquinolinyl-pyrrolidine-2,5-dione compounds. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or pyrroloquinolinyl-pyrrolidine-2,5-dione compound of the present invention.

  本发明涉及吡咯喹啉基吡咯-2,5-二酮化合物和吡咯喹啉基吡咯啉-2,5-二酮化合物，以及这些化合物的制备方法。本发明还涉及包含吡咯喹啉基吡咯-2,5-二酮化合物和吡咯喹啉基吡咯啉-2,5-二酮化合物的药物组合物。本发明提供了通过向需要治疗细胞增殖性疾病，如癌症的患者投与本发明的吡咯喹啉基吡咯-2,5-二酮化合物或吡咯喹啉基吡咯啉-2,5-二酮化合物的治疗有效量的方法。
• Compositions and Methods for Treatment of Cancer
  申请人：Li Chiang J.

  公开号：US20100221251A1

  公开（公告）日：2010-09-02

  The present invention relates to pyrroloquinolinyl-pyrrole-2,5-dione compounds and pyrroloquinolinyl-pyrrolidine-2,5-dione compounds, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising pyrroloquinolinyl-pyrrole-2,5-dione compounds and pyrroloquinolinyl-pyrrolidine-2,5-dione compounds. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or pyrroloquinolinyl-pyrrolidine-2,5-dione compound of the present invention.

  本发明涉及吡咯喹啉基吡咯-2,5-二酮化合物和吡咯喹啉基吡咯烷-2,5-二酮化合物及其制备方法。本发明还涉及包含吡咯喹啉基吡咯-2,5-二酮化合物和吡咯喹啉基吡咯烷-2,5-二酮化合物的制药组合物。本发明提供了通过向需要治疗细胞增殖性疾病，例如癌症的患者施用本发明的吡咯喹啉基吡咯-2,5-二酮化合物或吡咯喹啉基吡咯烷-2,5-二酮化合物的治疗有效量的方法。
• Maleimide derivatives, pharmaceutical compositions amd methods for treatment of cancer
  申请人：ArQule, Inc.

  公开号：EP2289892A1

  公开（公告）日：2011-03-02

  The present invention relates to pyrroloquinolinyl-pyrrole-2,5-dione compounds and pyrroloquinolinyl-pyrrolidine-2,5-dione compounds, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising pyrroloquinolinyl-pyrrole-2,5-dione compounds and pyrroloquinolinyl-pyrrolidine-2,5-dione compounds. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or pyrroloquinolinyl-pyrrolidine-2,5-dione compound of the present invention.

  本发明涉及吡咯喹啉基吡咯-2,5-二酮化合物和吡咯喹啉基吡咯烷-2,5-二酮化合物，以及这些化合物的制备方法。本发明还涉及包含吡咯喹啉基吡咯-2,5-二酮化合物和吡咯喹啉基吡咯烷-2,5-二酮化合物的药物组合物。本发明提供了治疗细胞增殖性疾病（如癌症）的方法，即向有需要的受试者施用治疗有效量的本发明的吡咯喹啉基吡咯-2,5-二酮化合物或吡咯喹啉基吡咯烷-2,5-二酮化合物。
• MALEIMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER
  申请人：ArQule, Inc.

  公开号：EP1846406B1

  公开（公告）日：2010-11-03
• A composition comprising (-)-trans-3-(5,6-dihydro-4h-pyrrolo [3,2,1-ij] quinolin-1-yl)-4-(1h-indol-3-yl) pyrrolidine-2, 5-dione in combination with sorafenib, sunitinib or erlotinib
  申请人：ArQule, Inc.

  公开号：EP2396003B1

  公开（公告）日：2013-04-17